Form 4: Olema Pharmaceuticals Director Cyrus Harmon Sells 20,000 Shares

Director Cyrus Harmon of Olema Pharmaceuticals sold 20,000 shares of common stock at an average price of $10.97, according to a recent SEC filing.

Summary

• On March 28, 2024, Cyrus Harmon, a director of Olema Pharmaceuticals, sold 20,000 shares of common stock.
• The sale was executed at a weighted average price of $10.97 per share, with prices ranging from $10.80 to $11.20.
• The transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on May 16, 2023.
• Following the transaction, Harmon directly owns 826,283 shares and indirectly owns 122,028 shares through Harmon Family Investors LLC.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale by a director under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.

Industry Context

Insider sales are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's future prospects. However, sales under 10b5-1 plans are pre-arranged and may not necessarily reflect the insider's current views.

Stakeholder Impact

• The sale of shares by a director could potentially create short-term selling pressure on the stock.
• Shareholders may interpret the sale as a lack of confidence in the company, although it is part of a pre-arranged trading plan.

Key Dates